SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a ZEGERID® branded omeprazole/sodium bicarbonate product in a 20 mg dosage strength of omeprazole. Schering-Plough is seeking FDA approval to sell the product in the U.S. over-the-counter (OTC) heartburn market, which is estimated at $1.6 billion in 2007 based on data from A.C. Nielsen, a market research firm, and company estimates.
